Search Results for "fluid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fluid. Results 41 to 48 of 48 total matches.

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
may have hypotension, shock, ileus, and/or megacolon) should receive fluid resuscitation and high-dose vancomycin ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction

Drugs for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance ...
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5   doi:10.58347/tml.2023.1672a |  Show IntroductionHide Introduction

Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
; detectable levels have been reported in human plasma, urine, breast milk, amniotic fluid, and fetal ...
In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild cognitive impairment or mild dementia, which was the population enrolled in the clinical trials. Now, Biogen, with the permission of the FDA, has made an addition to the labeling of the drug that says: Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical...
Med Lett Drugs Ther. 2021 Jul 26;63(1629):120 |  Show IntroductionHide Introduction

Antiviral Drugs for Seasonal Influenza for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
, swallowing, or clearing fluids from airways). Oseltamivir is preferred for treatment of influenza ...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8   doi:10.58347/tml.2024.1717a |  Show IntroductionHide Introduction

Influenza Vaccines for 2025-2026

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025  (Issue 1738)
with active communication between the cerebrospinal fluid (CSF) and oropharynx, nasopharynx, nose, or ear ...
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8   doi:10.58347/tml.2025.1738a |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
systemically; detectable levels have been reported in human plasma, urine, breast milk, amniotic fluid ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
-17 years old. 5. Should be taken with fluids. 6. Also approved for use in patients 6-17 years old ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
for exposure to blood or blood contaminated body fluids, persons on maintenance dialysis, persons ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction